These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29064081)

  • 1. Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney.
    Aoufi-Rabih S; García-Agudo R; Londoño MC; Fraga-Fuentes MD; Barril-Cuadrado G;
    J Nephrol; 2018 Feb; 31(1):1-13. PubMed ID: 29064081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD.
    Sise ME; Backman E; Ortiz GA; Hundemer GL; Ufere NN; Chute DF; Brancale J; Xu D; Wisocky J; Lin MV; Kim AY; Thadhani R; Chung RT
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1615-1623. PubMed ID: 28882857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.
    Li T; Qu Y; Guo Y; Wang Y; Wang L
    Liver Int; 2017 Jul; 37(7):974-981. PubMed ID: 27943605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Sofosbuvir-Based Regimens for the Treatment of Hepatitis C After Liver Transplant on Renal Function: Results of a Canadian National Retrospective Study.
    Faisal N; Bilodeau M; Aljudaibi B; Hirch G; Yoshida EM; Hussaini T; Ghali MP; Congly SE; Ma MM; Lilly LB
    Exp Clin Transplant; 2019 Feb; 17(1):59-63. PubMed ID: 29619910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).
    Minutolo R; Aghemo A; Chirianni A; Fabrizi F; Gesualdo L; Giannini EG; Maggi P; Montinaro V; Paoletti E; Persico M; Perticone F; Petta S; Puoti M; Raimondo G; Rendina M; Zignego AL; ; ; ;
    J Nephrol; 2018 Oct; 31(5):685-712. PubMed ID: 30255440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
    Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hepatitis C in special populations.
    Suda G; Ogawa K; Morikawa K; Sakamoto N
    J Gastroenterol; 2018 May; 53(5):591-605. PubMed ID: 29299684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.
    Fabrizi F; Martin P; Messa P
    Kidney Int; 2016 May; 89(5):988-994. PubMed ID: 27083277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).
    Minutolo R; Aghemo A; Chirianni A; Fabrizi F; Gesualdo L; Giannini EG; Maggi P; Montinaro V; Paoletti E; Persico M; Perticone F; Petta S; Puoti M; Raimondo G; Rendina M; Zignego AL;
    Dig Liver Dis; 2018 Nov; 50(11):1133-1152. PubMed ID: 30266305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.
    Deming P; Martin MT; Chan J; Dilworth TJ; El-Lababidi R; Love BL; Mohammad RA; Nguyen A; Spooner LM; Wortman SB
    Pharmacotherapy; 2016 Feb; 36(2):203-17. PubMed ID: 26846728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.
    Said M; Omar H; Soliman Z; Saad Y; Dabes H; Hamed S; ElSaeed K; ElShazly Y; ElSerafy M
    Expert Rev Gastroenterol Hepatol; 2019 Jan; 13(1):89-93. PubMed ID: 30791838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-acting antiviral drugs against hepatitis C virus in renal transplant recipients: Is it the dawn of an interferon-free Era?
    Rangaswamy D; Nagaraju SP; Attur RP
    Saudi J Kidney Dis Transpl; 2017; 28(5):1169-1174. PubMed ID: 28937081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).
    Minutolo R; Aghemo A; Chirianni A; Fabrizi F; Gesualdo L; Giannini EG; Maggi P; Montinaro V; Paoletti E; Persico M; Perticone F; Petta S; Puoti M; Raimondo G; Rendina M; Zignego AL; ; ; ;
    Intern Emerg Med; 2018 Dec; 13(8):1139-1166. PubMed ID: 30255464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
    Morisawa N; Koshima Y; Satoh JI; Maruyama Y; Kuriyama S; Yokoo T; Amemiya M
    Clin Exp Nephrol; 2017 Oct; 21(5):818-824. PubMed ID: 27771774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
    Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
    Orv Hetil; 2015 Mar; 156(9):343-51. PubMed ID: 25702254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations".
    Pol S; Parlati L
    Liver Int; 2018 Feb; 38 Suppl 1():28-33. PubMed ID: 29427485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: Therapy of HCV-recurrence.
    Teegen EM; Dürr M; Maurer MM; Eurich F; Vollbort A; Globke B; Bahra M; Blaeker H; Pratschke J; Eurich D
    Transpl Infect Dis; 2019 Feb; 21(1):e13020. PubMed ID: 30375710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.